Canada’s pharma failure: report confirms decades of high costs, declining research investment

Canadians pays significantly more for pharmaceutical drugs than consumers in many other developed countries and the promised increased investment in research and development has not materialized. Yet despite the costly state of affairs, the government is set to reward the industry with even stronger protections that will result in an extension of the higher prices.

By Michael Geist

PUBLISHED :Friday, Dec. 18, 2015 2:47 PM

If you are already a subscriber

Subscribe to The Hill Times

Subscribe to the digital and/or print editions and get instant access to The Hill Times online.

Quick Purchase

Purchase Story Issue in electronic format (PDF) for $5.00.